Credit Suisse Group began coverage on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research note issued to investors on Monday, Marketbeat.com reports. The brokerage issued a neutral rating and a $24.00 price target on the stock.
NTLA has been the topic of several other reports. Raymond James began coverage on Intellia Therapeutics in a research note on Thursday, September 20th. They issued a market perform rating on the stock. Zacks Investment Research lowered Intellia Therapeutics from a buy rating to a hold rating in a research note on Tuesday, August 7th. BidaskClub lowered Intellia Therapeutics from a buy rating to a hold rating in a research note on Friday, September 7th. Cann reaffirmed a hold rating on shares of Intellia Therapeutics in a research note on Thursday, October 18th. Finally, Chardan Capital reaffirmed a buy rating and issued a $57.50 price objective on shares of Intellia Therapeutics in a research note on Friday, August 24th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. Intellia Therapeutics has an average rating of Hold and an average price target of $35.50.
Shares of NTLA traded down $1.05 during trading hours on Monday, hitting $18.22. 19,697 shares of the company were exchanged, compared to its average volume of 593,503. The firm has a market cap of $803.21 million, a P/E ratio of -9.71 and a beta of 3.13. Intellia Therapeutics has a fifty-two week low of $16.33 and a fifty-two week high of $35.99.
Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Wednesday, October 31st. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.05). The company had revenue of $7.41 million for the quarter, compared to analyst estimates of $11.58 million. Intellia Therapeutics had a negative return on equity of 31.54% and a negative net margin of 284.56%. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period last year, the company posted ($0.44) earnings per share. As a group, equities analysts anticipate that Intellia Therapeutics will post -1.97 EPS for the current year.
Large investors have recently added to or reduced their stakes in the stock. Patriot Financial Group Insurance Agency LLC acquired a new stake in shares of Intellia Therapeutics during the third quarter valued at about $116,000. First Trust Advisors LP boosted its stake in shares of Intellia Therapeutics by 53.4% during the third quarter. First Trust Advisors LP now owns 160,303 shares of the company’s stock valued at $4,588,000 after purchasing an additional 55,798 shares in the last quarter. Chevy Chase Trust Holdings Inc. boosted its stake in shares of Intellia Therapeutics by 13.1% during the third quarter. Chevy Chase Trust Holdings Inc. now owns 742,024 shares of the company’s stock valued at $21,237,000 after purchasing an additional 86,142 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Intellia Therapeutics by 113.8% during the third quarter. Nisa Investment Advisors LLC now owns 17,100 shares of the company’s stock valued at $489,000 after purchasing an additional 9,100 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. acquired a new stake in shares of Intellia Therapeutics during the third quarter valued at about $141,000. 66.47% of the stock is currently owned by institutional investors and hedge funds.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Featured Article: Understanding Market Liquidity
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.